Joachim Hoechel
Overview
Explore the profile of Joachim Hoechel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
56
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen H, Chun D, Lingineni K, Guzy S, Cristofoletti R, Hoechel J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Nov;
13(11):2016-2025.
PMID: 39551952
Breakthrough bleeding (BTB) is a common side effect of hormonal contraception and is thought to impact adherence to combined oral contraceptives (COCs) but respective dose-response relationships are not yet fully...
2.
Cicali B, da Silva L, Sarayani A, Lingineni K, Pressly M, Kim S, et al.
Clin Pharmacol Ther
. 2022 Jun;
112(4):909-916.
PMID: 35723889
Worldwide, 922 million women of reproductive age (or their partners) use some sort of contraception to prevent pregnancy. Oral combined hormonal contraceptives (CHCs) typically utilize a combination of a progestin...
3.
Lingineni K, Chaturvedula A, Cicali B, Cristofoletti R, Wendl T, Hoechel J, et al.
Clin Pharmacol Ther
. 2021 Oct;
111(2):509-518.
PMID: 34674227
Combined oral contraceptive pills are the most commonly used hormonal contraceptives for the prevention of unintended pregnancies in United States. They consist of a progestin (e.g., levonorgestrel (LNG)) and an...
4.
Cicali B, Lingineni K, Cristofoletti R, Wendl T, Hoechel J, Wiesinger H, et al.
CPT Pharmacometrics Syst Pharmacol
. 2020 Nov;
10(1):48-58.
PMID: 33217171
Levonorgestrel (LNG) is the active moiety in many hormonal contraceptive formulations. It is typically coformulated with ethinyl estradiol (EE) to decrease intermenstrual bleeding. Due to its widespread use and CYP3A4-mediated...
5.
Liu H, Jiang J, Chen Z, Zhang Y, Li J, Hoechel J, et al.
Clin Pharmacol Drug Dev
. 2020 Jul;
10(5):486-493.
PMID: 32716091
Vilaprisan is a novel selective progesterone receptor modulator for the long-term treatment of uterine fibroids and endometriosis. This study investigated the pharmacokinetics, safety, and tolerability of vilaprisan in healthy Chinese...
6.
Joussen A, Wolf S, Kaiser P, Boyer D, Schmelter T, Sandbrink R, et al.
Br J Clin Pharmacol
. 2018 Oct;
85(2):347-355.
PMID: 30341774
Aims: This programme investigated topical regorafenib, a multikinase inhibitor, in patients with neovascular age-related macular degeneration (nAMD). Methods: Topical regorafenib was investigated in an open-label, phase IIa/b study in which...
7.
Schultze-Mosgau M, Schuett B, Hafner F, Zollmann F, Kaiser A, Hoechel J, et al.
Int J Clin Pharmacol Ther
. 2016 Nov;
55(1):16-24.
PMID: 27841155
Objectives: Vilaprisan is a novel, potent, and highly selective progesterone receptor modulator, which might offer a promising option for the treatment of uterine fibroids. Methods And Materials: In this randomized,...